▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #606 by analyst upside · 2026-11-13
VKTX
Viking Therapeutics, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+245.6%
implied upside to consensus target
Current Price $27.58
Consensus Target $95.32
Bull Target $125.0
Bear Target $34.0
Analysts Covering 19
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
13
Hold
2
Sell
0
52-Week Low $23.82
52-Week High $43.1
YTD Return -22.1%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-5.42
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $23.82
52-Week High $43.1
Current Price $27.58
Bear Target $34.0
Bull Target $125.0
● Now $27.58 ● Target $95.32
TRADING DATA
Avg Volume 5.1M
YTD Return -22.1%
Analyst Count 19
Consensus Buy
Upside to Target +245.6%
Last Updated 2026-11-13

ANALYST SUMMARY

Viking Therapeutics, Inc. (VKTX) is currently trading at $27.58 with a Wall Street consensus price target of $95.32, implying potential upside of 245.6% over the next 12 months. 19 analysts currently cover VKTX, with a consensus rating of Buy - 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $125.0, while the most cautious has a target of $34.0.

VKTX operates in the Healthcare sector with a market capitalisation of $4B. The stock is down 22.1% year-to-date and is currently trading near the lower end of its 52-week range of $23.82 – $43.1.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for VKTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-10-31 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-10-20 Building track record
UBS ● Initiated
Buy 2026-10-15 33% win rate (6 calls)
Truist Securities - Reiterated
Buy → Buy 2026-10-07 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-09-23 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-08-11 43% win rate (7 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-07-30 Building track record
Lake Street ● Initiated
Buy 2026-05-28 27% win rate (11 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
23/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →